Trial Outcomes & Findings for Safety and Efficacy of Repeated Administration of NurOwn (MSC-NTF Cells) in Participants With Progressive MS (NCT NCT03799718)

NCT ID: NCT03799718

Last Updated: 2023-12-04

Results Overview

Combined safety of all 3 intrathecal doses of NurOwn® (MSC-NTF cells) Number of participants who experienced Treatment-emergent Adverse Events during the study. Treatment-emergent Adverse Event is an adverse event that occurs for the first time after initiation of first treatment or if it had occurred prior to initiation first treatment, it worsens in severity after initiation of first treatment.

• Recruitment status: COMPLETED
• Study phase: PHASE2
• Target enrollment: 23 participants
• Primary outcome timeframe: Up to 28 weeks post-first treatment
• Results posted on: 2023-12-04

Participant Flow

Not meeting inclusion exclusion criteria

Unit of analysis: Treatments

Participant milestones

Measure	NurOwn (MSC-NTF Cells) Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors NurOwn (MSC-NTF cells). Study drug was supplied in one 5 mL syringe containing 4 mL of NurOwn (MSC-NTF cells) suspension at a dose of 100-125 x106 cells for IT administration. 3 doses of NurOwn (MSC-NTF cells) were transplanted intrathecally at 8-week intervals (Day 0-1, week 8, and week 16)
Overall Study STARTED	20 54
Overall Study COMPLETED	18 53
Overall Study NOT COMPLETED	2 1

Reasons for withdrawal

Measure	NurOwn (MSC-NTF Cells) Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors NurOwn (MSC-NTF cells). Study drug was supplied in one 5 mL syringe containing 4 mL of NurOwn (MSC-NTF cells) suspension at a dose of 100-125 x106 cells for IT administration. 3 doses of NurOwn (MSC-NTF cells) were transplanted intrathecally at 8-week intervals (Day 0-1, week 8, and week 16)
Overall Study Adverse Event	2

Baseline Characteristics

Safety and Efficacy of Repeated Administration of NurOwn (MSC-NTF Cells) in Participants With Progressive MS

Baseline characteristics by cohort

Measure	NurOwn (MSC-NTF Cells) n=18 Participants Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors NurOwn (MSC-NTF cells): Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors
Age, Continuous	47.4 years STANDARD_DEVIATION 9.6 • n=113 Participants
Sex: Female, Male Female	10 Participants n=113 Participants
Sex: Female, Male Male	8 Participants n=113 Participants
Ethnicity (NIH/OMB) Hispanic or Latino	0 Participants n=113 Participants
Ethnicity (NIH/OMB) Not Hispanic or Latino	18 Participants n=113 Participants
Ethnicity (NIH/OMB) Unknown or Not Reported	0 Participants n=113 Participants
Race (NIH/OMB) American Indian or Alaska Native	0 Participants n=113 Participants
Race (NIH/OMB) Asian	1 Participants n=113 Participants
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	0 Participants n=113 Participants
Race (NIH/OMB) Black or African American	2 Participants n=113 Participants
Race (NIH/OMB) White	15 Participants n=113 Participants
Race (NIH/OMB) More than one race	0 Participants n=113 Participants
Race (NIH/OMB) Unknown or Not Reported	0 Participants n=113 Participants
Region of Enrollment United States	18 Participants n=113 Participants
Timed 25-foot walk speed	2.4 Feet/seconds STANDARD_DEVIATION 1.6 • n=113 Participants
Nine-Hole Peg Test (9HPT)	35.2 Seconds STANDARD_DEVIATION 15.7 • n=113 Participants

PRIMARY outcome

Timeframe: Up to 28 weeks post-first treatment

Population: The primary, secondary, and exploratory efficacy endpoints were analyzed using the modified intent to treat (mITT) and Efficacy Evaluable (EE) populations The mITT population was defined in this study as all participants who received at least 1 treatment and had at least 1 T25FW or 9-HPT assessment post baseline. Baseline was defined as the most recent assessment prior to receiving the first transplantation on Day 0, at Visit 3

Combined safety of all 3 intrathecal doses of NurOwn® (MSC-NTF cells) Number of participants who experienced Treatment-emergent Adverse Events during the study.

Treatment-emergent Adverse Event is an adverse event that occurs for the first time after initiation of first treatment or if it had occurred prior to initiation first treatment, it worsens in severity after initiation of first treatment.

Outcome measures

Measure	NurOwn (MSC-NTF Cells) n=18 Participants Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors NurOwn (MSC-NTF cells): Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors
Number of Participants With Treatment-emergent Adverse Events	18 Participants

SECONDARY outcome

Timeframe: From Baseline (pre-first treatment) to 28 weeks post-first treatment

Population: The modified intent to treat (mITT) population was defined in this study as all participants who received at least 1 treatment and had at least 1 T25FW or 9-HPT assessment post baseline. Baseline was defined as the most recent assessment prior to receiving the first transplantation on Day 0, at Visit 3

25% or greater improvement at 28 weeks from Baseline in Time 25 Foot Walk (T25FW) speed or 9 Hole Peg Test (9-HPT).

The T25FW is a quantitative mobility and leg function performance test based on a timed 25-feet walk. The patient is directed to one end of a clearly marked 25-foot course and is instructed to walk 25 feet as quickly as possible, but safely. T25FW is the average of the two successive trials. Higher values represent better outcomes.

The 9HPT is used to measure upper extremity function in patients with various neurological diagnoses. The participant is asked to pick up the nine pegs, puts them in the nine holes, and, once completed, removes them again as quickly as possible, replacing them into the container. The total time to complete the task is recorded.

Higher values represent worse outcomes.

Outcome measures

Measure	NurOwn (MSC-NTF Cells) n=18 Participants Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors NurOwn (MSC-NTF cells): Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors
Number of Participants With 25% or Greater Improvement From Baseline in Time 25 Foot Walk (T25FW) Speed or Nine-Hole Peg Test (9-HPT) Number of Participants with 25% or greater improvement from Baseline inT25FW speed or 9-HPT	3 Participants
Number of Participants With 25% or Greater Improvement From Baseline in Time 25 Foot Walk (T25FW) Speed or Nine-Hole Peg Test (9-HPT) Number of Participants with <25% improvement from Baseline inT25FW speed or 9-HPT	13 Participants
Number of Participants With 25% or Greater Improvement From Baseline in Time 25 Foot Walk (T25FW) Speed or Nine-Hole Peg Test (9-HPT) Number of Participants with missing data at week 28	2 Participants

SECONDARY outcome

Timeframe: From Baseline (pre-first treatment) to 28 weeks post-first treatment

Population: mITT population

≥25% improvement in T25FW speed over 28 weeks The T25FW is a quantitative mobility and leg function performance test based on a timed 25-feet walk.

The patient is directed to one end of a clearly marked 25-foot course and is instructed to walk 25 feet as quickly as possible, but safely.

The task is immediately administered again by having the patient walk back the same distance Baseline T25FW is the average of the two successive trials. Higher values represent better outcomes

Outcome measures

Measure	NurOwn (MSC-NTF Cells) n=18 Participants Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors NurOwn (MSC-NTF cells): Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors
Number of Participants With 25% or Greater Improvement From Baseline to Week 28 in Timed 25 Foot Walk (T25FW) Speed Number of participants with missing values at week 28	4 Participants
Number of Participants With 25% or Greater Improvement From Baseline to Week 28 in Timed 25 Foot Walk (T25FW) Speed Number of participants with 25% or more improvement	2 Participants
Number of Participants With 25% or Greater Improvement From Baseline to Week 28 in Timed 25 Foot Walk (T25FW) Speed Number of participants without 25% or more improvement	12 Participants

SECONDARY outcome

Timeframe: From Baseline (pre-first treatment) to 28 weeks post-first treatment

Population: The mITT population was defined in this study as all participants who received at least 1 treatment and had at least 1 T25FW or 9-HPT assessment post baseline. Baseline was defined as the most recent assessment prior to receiving the first transplantation on Day 0, at Visit 3.

The Nine-Hole Peg Test (9HPT) is used to measure upper extremity function in patients with various neurological diagnoses.

The participant is seated at a table with a small, shallow container holding nine pegs and a wood or plastic block containing nine empty holes. On a start command when a stopwatch is started, the participant picks up the nine pegs one at a time as quickly as possible, puts them in the nine holes, and, once they are in the holes, removes them again as quickly as possible one at a time, replacing them into the shallow container. The total time to complete the task is recorded. Two consecutive trials with the dominant hand are immediately followed by two consecutive trials with the non-dominant hand.

Baseline 9HPT is the average of 2 trials of dominant hand and nondominant hand. The higher values represent a worse outcome.

Outcome measures

Measure	NurOwn (MSC-NTF Cells) n=18 Participants Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors NurOwn (MSC-NTF cells): Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors
Number of Participants With 25% or Greater Improvement From Baseline to Week 28 in 9-HPT Number of Participants with 25% or greater improvement from Baseline to Week 28 in 9-HPT	2 Participants
Number of Participants With 25% or Greater Improvement From Baseline to Week 28 in 9-HPT Number of Participants with less than 25% improvement from Baseline to Week 28 in 9-HPT	13 Participants
Number of Participants With 25% or Greater Improvement From Baseline to Week 28 in 9-HPT Number of participants with missing values at week 28	3 Participants

SECONDARY outcome

Timeframe: From Baseline (pre-first treatment) to 28 weeks post-first treatment

Population: The mITT population was defined in this study as all participants who received at least 1 treatment and had at least 1 T25FW or 9-HPT assessment post baseline. Baseline was defined as the most recent assessment prior to receiving the first transplantation on Day 0, at Visit 3. The participants in mITT population whose EDSS Score was \>5.5 at Baseline was analyzed.

Expanded Disability Status Scale (EDSS) provides a total score on a scale that ranges from 0 (no disability) through 1 to 10 (death due to MS), in 0.5-point steps. The first levels 1.0 to 4.5 refer to people with a high degree of ambulatory ability and the sequent levels 5.0 to 9.5 refer to the loss of ambulatory ability. The higher score represents the worse outcome.

Outcome measures

Measure	NurOwn (MSC-NTF Cells) n=10 Participants Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors NurOwn (MSC-NTF cells): Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors
Number of Participants Who Had >5.5 in Expanded Disability Status Scale (EDSS) at Baseline, With ≥0.5 Points Improvement From Baseline to Week 28 No of Participants with >5.5 in EDSS at Baseline with ≥0.5 Points Improvement from Baseline to Wk 28	3 Participants
Number of Participants Who Had >5.5 in Expanded Disability Status Scale (EDSS) at Baseline, With ≥0.5 Points Improvement From Baseline to Week 28 No of Participants with >5.5 in EDSS at Baseline with <0.5 Points Improvement from Baseline to Wk 28	7 Participants

SECONDARY outcome

Timeframe: From Baseline (pre-first treatment) to 28 weeks post-first treatment

Population: The mITT population was defined in this study as all participants who received at least 1 treatment and had at least 1 T25FW or 9-HPT assessment post baseline. Baseline was defined as the most recent assessment prior to receiving the first transplantation on Day 0, at Visit 3

The Multiple Sclerosis Walking Scale (MSWS)-12 is a patient-reported outcome measure of the walking limitations due to MS during the past 2 weeks.

It contains 12 questions that assess the impact of MS on different aspects of walking function and quality.

Total administration time should be approximately 5 minutes. Activities are rated by participant from min. 1 (not at all) to max. 5 (extremely) and summed to calculate a total score using a scale from 0 to 60 (ranging from low to high impact on walking). This score is then divided by 60 and multiplied by 100 to get a score between 0 and 100 A higher score represents a worse outcome.

Outcome measures

Measure	NurOwn (MSC-NTF Cells) n=18 Participants Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors NurOwn (MSC-NTF cells): Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors
Number of Participants With ≥10 Points Improvement From Baseline to Week 28 in Multiple Sclerosis Walking Scale (MSWS-12) Number of Participants with ≥10 Points Improvement from Baseline to Week 28 in MSWS-12	6 Participants
Number of Participants With ≥10 Points Improvement From Baseline to Week 28 in Multiple Sclerosis Walking Scale (MSWS-12) Number of Participants with <10 Points Improvement from Baseline to Week 28 in MSWS-12	10 Participants
Number of Participants With ≥10 Points Improvement From Baseline to Week 28 in Multiple Sclerosis Walking Scale (MSWS-12) Number of Participants with missing data at week 28	2 Participants

SECONDARY outcome

Timeframe: From Baseline (pre-first treatment) to 28 weeks post-first treatment

Population: The mITT population was defined in this study as all participants who received at least 1 treatment and had at least 1 T25FW or 9-HPT assessment post baseline. Baseline was defined as the most recent assessment prior to receiving the first transplantation on Day 0, at Visit 3

The Low contrast letter acuity (LCLA) is a leading outcome measure to assess visual disability in multiple sclerosis (MS) research Total administration time, for a typical MS patient, is approximately 10-15 minutes to complete, when testing each eye individually and binocular vision for two different contrast levels.

The score for each chart is quantified as the number of letters identified correctly with a minimum scrore of 0 letter and a maximum score of 70 letters. The higher score represents the better outcome.

Outcome measures

Measure	NurOwn (MSC-NTF Cells) n=18 Participants Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors NurOwn (MSC-NTF cells): Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors
Number of Participants With ≥8 Letter Improvement From Baseline to Week 28 in LCLA Binocular 2.5% Contrast Level No. of participants with ≥8 Letter improvement at Week 28 in LCLA Binocular 2.5% Contrast Level	4 Participants
Number of Participants With ≥8 Letter Improvement From Baseline to Week 28 in LCLA Binocular 2.5% Contrast Level No. of Participants with <8 Letter Improvement at week 28 in LCLA Binocular 2.5% Contrast Level	11 Participants
Number of Participants With ≥8 Letter Improvement From Baseline to Week 28 in LCLA Binocular 2.5% Contrast Level Number of Participants with missing data at week 28	3 Participants

SECONDARY outcome

Timeframe: From Baseline (pre-first treatment) to 28 weeks post-first treatment

Population: The mITT population was defined in this study as all participants who received at least 1 treatment and had at least 1 T25FW or 9-HPT assessment post baseline. Baseline was defined as the most recent assessment prior to receiving the first transplantation on Day 0, at Visit 3.

Symbol Digit Modalities test (SDMT) is a commonly used test to assess psychomotor speed, which measures processing speed as well as motor speed.

It is a paper-pencil measure which requires an individual to substitute digits for abstract symbols using a reference key Scoring involves summing the number of correct substitutions within the 90 second interval (max = 110) Minimum score is 0 and maximum score 110. The higher score represents the better outcome.

Outcome measures

Measure	NurOwn (MSC-NTF Cells) n=18 Participants Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors NurOwn (MSC-NTF cells): Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors
Number of Participants With ≥ 3 Points Improvement From Baseline to Week 28 in Symbol Digit Modalities Test (SDMT) Score Number of Participants with ≥ 3 points Improvement from Baseline to Week 28 in SDMT Score	10 Participants
Number of Participants With ≥ 3 Points Improvement From Baseline to Week 28 in Symbol Digit Modalities Test (SDMT) Score Number of Participants with < 3 points Improvement from Baseline to Week 28 in SDMT Score	5 Participants
Number of Participants With ≥ 3 Points Improvement From Baseline to Week 28 in Symbol Digit Modalities Test (SDMT) Score Number of Participants with missing data at week 28	3 Participants

SECONDARY outcome

Timeframe: From Baseline (pre-first treatment) to 16 weeks post first treatment

Population: mITT Population with data available at week 16

Change from baseline (pre-first treatment) in the concentration of Vascular endothelial growth factor (VEGF) neuroprotective biomarker in the Cerebrospinal fluid (CSF) at 16 weeks following first NurOwn® treatment The concentration of the biomarker is measured as Picogram per milliliter (pg/ml). A higher concentration of neuroprotective biomarkers suggests a better outcome

Outcome measures

Measure	NurOwn (MSC-NTF Cells) n=17 Participants Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors NurOwn (MSC-NTF cells): Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors
Change in Concentration of Vascular Endothelial Growth Factor (VEGF) Neuroprotective Biomarker From Baseline in the Cerebrospinal Fluid (CSF) 16 Weeks Following First NurOwn® Treatment	90.17 Picograms per milliliter Interval -9.16 to 124.8

SECONDARY outcome

Timeframe: From Baseline (pre-first treatment) to 16 weeks post first treatment

Population: mITT population with data available at week 16

Change from baseline in the concentration of Hepatocyte growth factor (HGF) neuroprotective biomarker in the Cerebrospinal Fluid (CSF) at 16 weeks following the first NurOwn® treatment The concentration of the biomarker is measured as Picogram per milliliter (pg/ml). A higher concentration of neuroprotective biomarkers suggests a better outcome

Outcome measures

Measure	NurOwn (MSC-NTF Cells) n=17 Participants Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors NurOwn (MSC-NTF cells): Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors
Change in Concentration of Hepatocyte Growth Factor (HGF) Neuroprotective Biomarker From Baseline in the Cerebrospinal Fluid (CSF) 16 Weeks Following NurOwn® Treatment	15.16 picograms per milliliter Interval 0.2 to 19.44

Adverse Events

NurOwn (MSC-NTF Cells)

Serious events: 2 serious events

Other events: 18 other events

Deaths: 0 deaths

Serious adverse events

Measure

NurOwn (MSC-NTF Cells) n=18 participants at risk Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors NurOwn (MSC-NTF cells): Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors

Nervous system disorders Arachnoiditis

11.1% 2/18 • Number of events 2 • 28 weeks Adverse Events (AE) were collected over a period of 38 weeks from the time of informed consent at the screening visit through the last study visit (Visit 7 or an Early Termination visit) Treatment Emergent Adverse Events (TEAE) were collected over a period of 28 weeks from the time of the first treatment through the last study visit (Visit 7 or an Early Termination visit)

Other adverse events

Measure	NurOwn (MSC-NTF Cells) n=18 participants at risk Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors NurOwn (MSC-NTF cells): Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors
Nervous system disorders Headache	88.9% 16/18 • Number of events 35 • 28 weeks Adverse Events (AE) were collected over a period of 38 weeks from the time of informed consent at the screening visit through the last study visit (Visit 7 or an Early Termination visit) Treatment Emergent Adverse Events (TEAE) were collected over a period of 28 weeks from the time of the first treatment through the last study visit (Visit 7 or an Early Termination visit)
Musculoskeletal and connective tissue disorders Back pain	83.3% 15/18 • Number of events 29 • 28 weeks Adverse Events (AE) were collected over a period of 38 weeks from the time of informed consent at the screening visit through the last study visit (Visit 7 or an Early Termination visit) Treatment Emergent Adverse Events (TEAE) were collected over a period of 28 weeks from the time of the first treatment through the last study visit (Visit 7 or an Early Termination visit)
Infections and infestations Urinary tract infection	33.3% 6/18 • Number of events 8 • 28 weeks Adverse Events (AE) were collected over a period of 38 weeks from the time of informed consent at the screening visit through the last study visit (Visit 7 or an Early Termination visit) Treatment Emergent Adverse Events (TEAE) were collected over a period of 28 weeks from the time of the first treatment through the last study visit (Visit 7 or an Early Termination visit)
Musculoskeletal and connective tissue disorders Musculoskeletal pain	27.8% 5/18 • Number of events 5 • 28 weeks Adverse Events (AE) were collected over a period of 38 weeks from the time of informed consent at the screening visit through the last study visit (Visit 7 or an Early Termination visit) Treatment Emergent Adverse Events (TEAE) were collected over a period of 28 weeks from the time of the first treatment through the last study visit (Visit 7 or an Early Termination visit)
General disorders Injection site pain	22.2% 4/18 • Number of events 4 • 28 weeks Adverse Events (AE) were collected over a period of 38 weeks from the time of informed consent at the screening visit through the last study visit (Visit 7 or an Early Termination visit) Treatment Emergent Adverse Events (TEAE) were collected over a period of 28 weeks from the time of the first treatment through the last study visit (Visit 7 or an Early Termination visit)
General disorders Pyrexia	22.2% 4/18 • Number of events 5 • 28 weeks Adverse Events (AE) were collected over a period of 38 weeks from the time of informed consent at the screening visit through the last study visit (Visit 7 or an Early Termination visit) Treatment Emergent Adverse Events (TEAE) were collected over a period of 28 weeks from the time of the first treatment through the last study visit (Visit 7 or an Early Termination visit)
Musculoskeletal and connective tissue disorders Arthralgia	16.7% 3/18 • Number of events 3 • 28 weeks Adverse Events (AE) were collected over a period of 38 weeks from the time of informed consent at the screening visit through the last study visit (Visit 7 or an Early Termination visit) Treatment Emergent Adverse Events (TEAE) were collected over a period of 28 weeks from the time of the first treatment through the last study visit (Visit 7 or an Early Termination visit)
Injury, poisoning and procedural complications Fall	16.7% 3/18 • Number of events 4 • 28 weeks Adverse Events (AE) were collected over a period of 38 weeks from the time of informed consent at the screening visit through the last study visit (Visit 7 or an Early Termination visit) Treatment Emergent Adverse Events (TEAE) were collected over a period of 28 weeks from the time of the first treatment through the last study visit (Visit 7 or an Early Termination visit)
General disorders Fatigue	16.7% 3/18 • Number of events 3 • 28 weeks Adverse Events (AE) were collected over a period of 38 weeks from the time of informed consent at the screening visit through the last study visit (Visit 7 or an Early Termination visit) Treatment Emergent Adverse Events (TEAE) were collected over a period of 28 weeks from the time of the first treatment through the last study visit (Visit 7 or an Early Termination visit)
Musculoskeletal and connective tissue disorders Muscular weakness	16.7% 3/18 • Number of events 4 • 28 weeks Adverse Events (AE) were collected over a period of 38 weeks from the time of informed consent at the screening visit through the last study visit (Visit 7 or an Early Termination visit) Treatment Emergent Adverse Events (TEAE) were collected over a period of 28 weeks from the time of the first treatment through the last study visit (Visit 7 or an Early Termination visit)
Musculoskeletal and connective tissue disorders Musculoskeletal stiffness	16.7% 3/18 • Number of events 3 • 28 weeks Adverse Events (AE) were collected over a period of 38 weeks from the time of informed consent at the screening visit through the last study visit (Visit 7 or an Early Termination visit) Treatment Emergent Adverse Events (TEAE) were collected over a period of 28 weeks from the time of the first treatment through the last study visit (Visit 7 or an Early Termination visit)
Musculoskeletal and connective tissue disorders Pain in extremity	16.7% 3/18 • Number of events 4 • 28 weeks Adverse Events (AE) were collected over a period of 38 weeks from the time of informed consent at the screening visit through the last study visit (Visit 7 or an Early Termination visit) Treatment Emergent Adverse Events (TEAE) were collected over a period of 28 weeks from the time of the first treatment through the last study visit (Visit 7 or an Early Termination visit)

Additional Information

Chief Medical Officer

Brainstorm Cell therapeutics

Phone: 201-488-0460

Email: Clinical.Trial@brainstorm-cell.com

Results disclosure agreements

• Principal investigator is a sponsor employee
• Publication restrictions are in place

Restriction type: GT60